Introduction
For nearly 25 years, researchers have sought the cause of Reye syndrome, an often fatal disease that strikes children after a viral illness (1) (2) (3) (4) (5) . In recent years, many investigators have focused their search on the liver, in which disturbances in lipid metabolism may play a role in either the cause or the pathology of the disease.
One of the primary characteristics of Reye syndrome is an abnormally high level of circulating FFA (1) (2) (3) (4) (5) . Other disturbances point directly to impaired fatty acid oxidation in the liver. For example, blood levels off-hydroxybutyrate and acetoacetate, end products of jB-oxidation by liver cells, are depressed in these patients (2) . The patients' urine also contains unusual short-and medium-chain' fatty acids and their metabolites (2, 6, 7) ; the former compounds normally are oxidized in the liver. Finally, hepatocytes show an increase in both lipid droplets and peroxisomes (1) (2) (3) (4) (5) . Peroxisomes are secondary sites of fatty acid oxidation (8, 9) .
How might these perturbations in fatty acid oxidation be involved in the pathology of Reye syndrome? A clear causal relationship has not been established, but at least one intriguing hypothesis exists. The unusual fatty acids excreted by Reye patients, such as propionate, butyrate, and octanoate, are derived from acyl CoA precursors. As these precursors accumulate, they could compete for enzyme-binding sites with acetyl CoA or other acyl CoA substrates, profoundly disrupting normal biochemical pathways for energy metabolism and ureogenesis (10) (11) (12) .
To explore this hypothesis, we developed a sensitive method to measure the short-and medium-chain acyl CoA esters in liver biopsy specimens from patients with Reye syndrome. The method, never before applied to human tissue, also was used on control subjects undergoing liver biopsy for other reasons. A third group of patients with medium-chain acyl CoA dehydrogenase (MCAD)2 deficiency was evaluated.
In this congenital disease, one of the essential enzymes of mitochondrial p3-oxidation is missing, causing many of the same signs as Reye syndrome (13, 14) .
The goal of this research was to determine whether or not acyl CoA esters, possible inhibitors of several metabolic pathways, accumulate in livers of patients with Reye syndrome. The measurements may be correlated with the deacylated metabolites previously found in the blood and urine of these patients and with clinical manifestations of the disease.
Another objective was to pinpoint the biochemical defects responsible for altered fatty acid metabolism in Reye syndrome. Finally, the measurements may illuminate, on a biochemical level, further differences between Reye syndrome and MCAD deficiency, diseases that can be hard to differentiate clinically (15 This report demonstrates abnormal acyl CoA profiles in patients with Reye syndrome. It also presents a hypothesis to explain how these unusual metabolites may be involved in the pathogenesis of Reye syndrome. A general model also was developed to show the cooperative interactions of the three pathways of hepatic fatty acid oxidation: mitochondrial ,B-oxidation, peroxisomal ,-oxidation, and microsomal w-oxidation.
Methods
Patients. Patients with Reye syndrome were identified by criteria set forth by the Communicable Disease Center (2) . Informed consent for participation in this study was obtained from the parents or guardians of patients undergoing diagnostic liver biopsy. The additional portion of liver used for this study entailed no additional risk for the patient. The clinical characteristics of these patients are shown in Table I . The two patients with MCAD deficiency and one control subject (C-1) have been described previously (13, 14) . Four additional subjects (Table II) were subjected to liver biopsy in the course ofestablishing diagnoses of chronic hepatitis (C-2), hypopituitarism (C-3), Hodgkin's lymphoma (C-4), and muscular dystrophy (C-5). The control, C-5, had been fasted overnight before biopsy and was previously evaluated for acyl CoA dehydrogenase deficiency and found to have normal enzyme levels.
Sample preparation. Because of the small samples available from human subjects, a decision was made to measure short-and mediumchain fatty acyl CoA esters, rather than long-chain compounds. This choice was based on two main considerations. First, a previous study by Kang et al. (16) showed no differences in levels of long-chain acyl CoA compounds in necropsy liver samples, between control subjects and Reye syndrome patients. Second, abnormal urinary metabolites in these patients are derived from short-and medium-chain compounds, not long-chain esters.
Samples were obtained by needle biopsy, frozen in liquid nitrogen within 2 min after removal from the patient, and stored at -70'C. Samples were prepared for analysis as follows: 10-20 mg frozen tissue was rapidly weighed and then extracted with 0.4 ml of ice-cold 0.6 N TCA. Each sample was briefly sonicated in an ice bath until a homogeneous mixture was obtained, using -10 bursts of 1-3 s with a microtip at a setting of 4 (model W185 F sonicator cell disrupter, Heat Systems-Ultrasonics, Inc., Plainview, NY). The acid-insoluble residue was removed by centrifugation at 12,000 g for 30 s. These pellets were washed several times with ether, dried overnight, and weighed to determine fat-free dry weight. Dry weight averaged 17.8±2.2% (SD) of wet weight and was similar in all samples. The supernatant was neutralized and the TCA was removed by vigorous vortexing with 0.6 ml 
(buffer B). Elution of acid-soluble
CoA esters from malonyl CoA to octanoyl CoA was achieved by varying both the gradient and the rate of flow. The initial composition of the mobile phase was 7.5% buffer B. This was increased to 10% at 22 min (over 1 min) and to 80% at 50 min (over 40 min). The initial flow rate was 0.4 ml/min. This was increased to 0.8 ml/min at 20 min (over 1 min) and to 1.2 ml/min at 55 min (over 5 min).
Identification A more rapid separation of esters with earlier elution times was not feasible, due to interference from abundant absorbing material that eluted during the first 15 min. This is illustrated in the chromato6ram of Fig. 2 for a typical biopsy sample representing -20 mg (wet weight) ofliver. Note the elution of numerous peaks during the early portion ofthe chromatogram that were mainly adenine and pyridine nucleotides. Separation and identification of the early eluting adenine and pyridine nucleotide peaks requires a longer elution period in straight buffer without acetonitrile (18), which was not done in these studies. The large, unidentified peak at 58 min probably represented flavin nucleotides, since it coeluted with a flavin nucleotide'standard (data not shown) and was retained after alkaline hydrolysis (19, 20) .
The individual acyl CoA values from 10 human subjects and the' Wean values for each of the three patient groups, are shown in Table III In the two patients with MCAD deficiency, the levels of both free CoASH and succinyl CoA were similar to control subjects. However, acetyl CoA levels were markedly depressed, representing only 4% of the total pool. As a result, the ratio of CoASH to acetyl CoA rose fourfold from control levels to 16. Compared with control subjects, MCAD patients showed an increase in methylmalonyl CoA, representing 5% of the total pool. Several acyl CoA compounds, including octanoyl CoA, were not measured in these patients.3
The acyl CoA profiles ofthe three Reye syndrome patients were distinct from the other two groups. Unlike control subjects, these patients accumulated unusual CoA esters, including methylmalonyl, propionyl, (iso)butyryl, isovaleryl, and octanoyl CoA. In these patients, the absolute levels of acetyl CoA, averaging 24 nmol/g were about half the control value. Still, acetyl CoA was the major metabolite, representing -25% ofthe total pool. Free CoASH levels were dramatically reduced in these patients to -11 nmol/g, or < 10% of the control levels. Largely due to the drop in free CoASH, the ratio of free CoASH to acetyl CoA fell to -0.5, or 10% of the control value. 3 . MCAD liver biopsy samples were analyzed before identification of the enzyme deficiency and before expansion of the assay to include octanoyl CoA. Subsequent studies on fibroblasts obtained from these patients, incubated in media containing FFA demonstrated accumulation of octanoyl CoA.
The Reye syndrome patients also had a dramatic reduction in the total soluble pool of short-and medium-chain acyl CoA esters. The average size of the pool was 90 nmol/g, or onethird of control values. The method did not distinguish between a decrease caused by a drop in the combined acid-soluble and -insoluble pools, or by an increase of CoA in the unmeasured insoluble pool, which contained the long-chain acyl CoA metabolites. 
Discussion
This study demonstrated, for the first time, the measurement of acyl CoA esters in human liver biopsy samples. Use of the method to probe fatty acid oxidation in human subjects offers several advantages over previous techniques. First, since the biopsy samples were quickly frozen, the tissue underwent far less cellular autolysis than in a previous postmortem study (16) . The method also permits identification of specific shortand medium-chain acyl CoA compounds, whereas prior techniques measured the entire pool (16, 20) . The biopsy method also can be used to study earlier stages ofthe disease, providing insight into the progression of the pathology.
The study also showed a striking similarity between rat and human acyl CoA profiles, suggesting that the rat may be a useful animal model for investigation of Reye syndrome. So far, efforts to study the disease have been hampered by lack of an animal model in which to test hypotheses of pathogenesis (2) . A rat model also would permit correlation of biochemical and morphological events. Measured levels of acyl CoA compounds supported the hypothesis that fatty acid oxidation is compromised in Reye syndrome patients (2, 7) . The unusual short-and mediumchain acyl CoA esters that accumulated in the livers are likely precursors of the deacylated compounds previously reported in the blood and urine of these patients (2) (3) (4) (5) (6) (7) . At least three explanations are possible for the unusual acyl CoA profiles in these patients. One possibility is a generalized increase in proteolysis. Protein breakdown would lead to increased production of branched-chain amino and ketoacids, precursors to several ofthe compounds observed in this study, including isovaleryl, isobutyryl, propionyl, and methylmalonyl CoA (10, 17) . Contradicting the occurrence of widespread proteolysis was the failure to detect a generalized increase in other metabolites of branched-chain ketoacid oxidation.
Alternatively, a multiple acyl CoA dehydrogenation defect (glutaric acid-uria type II), caused by deficiency of electron transfer flavoprotein or electron transfer flavoprotein dehydrogenase, could account for the unusual organic aciduria (21) . This disorder is characterized by accumulation and excretion of organic acids derived from acyl CoA substrates of mitochondrial acyl CoA dehydrogenases. However, additional compounds that are not substrates of these enzymes also appear in the urine of patients with Reye syndrome.
The final, and most likely hypothesis is a multiple-site inhibition ofthe mitochondrial enzymes involved in fatty acid and branched-chain amino acid metabolism. Morphological and biochemical evidence support this concept. The pleomorphic mitochondria found in Reye syndrome patients show disrupted cristae (22) , sites of the membrane-associated acyl CoA dehydrogenases of both branched-chain and fatty acid oxidation (23, 24 (10) (11) (12) . It is not known if these mitochondrial enzymes are membrane associated.
Given the evidence for impaired fatty acid oxidation in Reye syndrome, the near normal levels of acetyl CoA in these patients were surprising. One explanation for this puzzle may be increased production of cytosolic acetyl CoA. Acetyl CoA concentration gradients between mitochondria and cytosol vary from 6.6 to 25 in hepatocytes from fed rats, depending on substrate (25) . While mitochondrial fatty acid oxidation is inhibited, alternative pathways thus may have stepped up production of acetyl CoA. If so, peroxisomes would be likely sites for this extramitochondrial activity, since these organelles oxidize fatty acids (8, 9) and proliferate in Reye syndrome (22) . Fatty acid oxidation by peroxisomes also is limited to substrates ofchain length . 8 (8, 9) , consistent with the absence of long-chain acyl CoA ester accumulation in patients with Reye syndrome (16) . Other evidence for a peroxisomal pathway is the abnormally high levels of acetyl carnitine, a presumed end product of peroxisomal fatty acid oxidation, excreted by these patients (26, 27) .
Alternatively, acetyl CoA might accumulate to near normal levels due to blockade of its conversion to acetoacetate. However, no intermediates of the ketogenic pathway were detected, a finding consistent with the known low rate of ketogenesis in Reye syndrome.
The results of this study are summarized in the model shown in Fig. 3 . We postulate that mitochondrial (i-oxidation is blocked at multiple acyl CoA dehydrogenases, resulting in accumulation of short-, medium-, and long-chain acyl CoA compounds. Since short-and some medium-chain acyl CoA esters are not substrates for peroxisomal /3-oxidation (8, 9) , they would either be degraded in the microsomes by w-oxidation or deacylated and excreted. Long-chain fatty acyl CoA esters would not accumulate in this scheme, but instead would be oxidized in the peroxisomes. That would explain why acetyl carnitine appears in the urine, but ketone bodies, the end products of mitochondrial fatty acid oxidation, do not accumulate normally (2, 27) .
The model also could explain findings in disorders of fatty acid metabolism in patients with long-chain acyl CoA dehydrogenase or MCAD deficiency. In long-chain acyl CoA dehydrogenase deficiency the first enzyme of mitochondrial ,8-oxidation is defective (28) . Such patients excrete acetyl carnitine in the urine, consistent with the idea that peroxisomal /3-oxidation is involved. Medium-chain dicarboxylic acids are also excreted by these patients. The model would predict that these compounds are derived from accumulated medium-chain acyl CoA esters, end products of peroxisomal /3-oxidation, which are subsequently degraded by w-oxidation to dicarboxylic acids. In patients with MCAD deficiency, a partial block of mitochondrial /3-oxidation would result in diminished acetyl
CoA levels, as shown in this study, and decreased ketone body levels, as reported previously (13) . Because of the block, mitochondrial fatty acid oxidation can proceed only to mediumchain fatty acyl CoA esters. Since these compounds cannot be further degraded by the peroxisomes, they would be metabolized and excreted as medium-chain acyl carnitines and dicarboxylic acids. This idea is consistent with the reported presence of octanoyl carnitine and dicarboxylic acids in the urine of MCAD patients (29, 30) .
The findings also provide potential mechanisms for several major abnormalities observed in Reye syndrome. The hyperammonemia found in these patients (1) (2) (3) (4) (5) could result from the observed accumulation of methylmalonyl and propionyl CoA esters, since these compounds inhibit two key enzymes in ureogenesis, carbamyl phosphate synthetase I and N-acetylglutamate synthetase (10) (11) (12) . Likewise, the hypoglycemia observed in Reye syndrome (1-5) could result from the accumulation of methylmalonyl CoA, since it inhibits pyruvate carboxylase (10) (11) (12) , the first and rate-limiting enzyme in gluconeogenesis. Finally, the very low ratios of CoASH/acetyl CoA observed in Reye syndrome patients could inhibit mitochondrial energy generation (10-12, 31, 32) . Flux through pyruvate dehydrogenase and a-ketoglutarate dehydrogenase, two enzymes involved in ATP production, are regulated by CoASH levels. High levels ofpropionyl CoA and methylmalonyl CoA also could inhibit citrate synthase, another Krebs cycle enzyme (10) (11) (12) . Since both ureogenesis and gluconeogenesis require mitochondrial ATP, secondary inhibition of these pathways could also result from energy deficiency.
Still to be determined is the trigger that initiates this cascade of events in Reye syndrome. A genetic defect, viral infection, salicylate toxicity, and endotoxin are among the factors suggested as possible causes of the disease (33) (34) (35) (36) (37) (38) (39) . One intriguing candidate is tumor necrosis factor (TNF). TNF production follows viral infection or endotoxin stimulation (35, 38) , conditions that also precede Reye syndrome. Moreover, the ingestion ofaspirin, which also stimulates TNF production (35) , usually precedes the onset of the disease. Whatever the causative factor, the findings in this study put constraints on future models, which must account for the unusual pattern of acyl CoA esters found in Reye syndrome.
